A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis (DCM ) Treated With Olorofim Plus Baseline SOC or Placebo Plus Baseline SOC

The purpose of this study is to test measurement tools (questionnaire about symptoms and a questionnaire about quality of life) to assess usability in the assessment of treatment effectiveness for people with disseminated coccidioidomycosis (DCM).

Inclusion Criteria: * Male and female patients, English- or Spanish-speaking, aged ≥18 years and weighing ≥40 kg. * Patients with progressive or refractory disseminated coccidioidomycosis (DCM) involving extra-pulmonary sites with or without ongoing active disease in lungs. * Standard of Care therapy for DCM to date has included 2 different triazoles (with or without a course of intravenous amphotericin B). Exclusion Criteria: * Patients who are unconscious. * Women who are pregnant or breastfeeding. * Known history of allergy, hypersensitivity, or any serious reaction to any component of the study drug. * Patients with or planned placement of indwelling CNS devices. * Patients receiving intrathecal amphotericin B at the time of study enrolment. * Coccidioidomycosis limited to fibro-cavitary pulmonary disease. * All bothersome DCM-related symptoms at study entry are due to irreversible damage (e.g., neurologic deficits due to stroke). * Other than cutaneous fungal infections treated topically and Pneumocystis jirovecii infections, patients with a second fungal infection requiring systemic antifungal treatment or prophylaxis. * Patients with microbiological findings or other potential conditions that are temporally related and suggest a different than study indication etiology for the clinical features. * Patients living with Human immunodeficiency virus (HIV) unless for at least 6 months prior to enrollment: 1. Are receiving antiretroviral therapy AND 2. Have no evidence of current clinical progression resulting from HIV infection. * Patients who have received prior treatment with olorofim/F901318. * Patients receiving treatment limited to supportive care due to predicted short survival time. * Patients with a baseline prolongation of QT using Fridericia's Correction Formula (QTcF) ≥500 msec, or at high risk for QT/QTc prolongation. * Evidence of hepatic dysfunction.